Global Peptide CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032
Description
According to our (Global Info Research) latest study, the global Peptide CDMO market size was valued at US$ 4944 million in 2025 and is forecast to a readjusted size of US$ 12710 million by 2032 with a CAGR of 14.6% during review period.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.
Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.
This report is a detailed and comprehensive analysis for global Peptide CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Peptide CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Peptide CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Peptide CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Peptide CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
APIs and Intermediates
FDF
Market segment by Application
Commercial
Academic Research
Other
Market segment by players, this report covers
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Peptide CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Peptide CDMO, with revenue, gross margin, and global market share of Peptide CDMO from 2021 to 2026.
Chapter 3, the Peptide CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Peptide CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide CDMO.
Chapter 13, to describe Peptide CDMO research findings and conclusion.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.
Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.
This report is a detailed and comprehensive analysis for global Peptide CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Peptide CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Peptide CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Peptide CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Peptide CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Peptide CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
APIs and Intermediates
FDF
Market segment by Application
Commercial
Academic Research
Other
Market segment by players, this report covers
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Peptide CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Peptide CDMO, with revenue, gross margin, and global market share of Peptide CDMO from 2021 to 2026.
Chapter 3, the Peptide CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Peptide CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide CDMO.
Chapter 13, to describe Peptide CDMO research findings and conclusion.
Table of Contents
102 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
